|
gptkbp:instanceOf
|
gptkb:drug
opioid
|
|
gptkbp:antidote
|
heroin overdose
morphine overdose
fentanyl overdose
hydrocodone overdose
other opioid overdose
oxycodone overdose
|
|
gptkbp:approvedBy
|
1971
|
|
gptkbp:ATCCode
|
V03AB15
|
|
gptkbp:bioavailability
|
100% (IV)
2% (oral)
35% (intranasal)
|
|
gptkbp:brand
|
gptkb:Narcan
gptkb:Evzio
|
|
gptkbp:CASNumber
|
465-65-6
|
|
gptkbp:chemicalClass
|
opioid
|
|
gptkbp:contraindication
|
hypersensitivity to naloxone
|
|
gptkbp:developedBy
|
gptkb:Janssen_Pharmaceutica
|
|
gptkbp:eliminationHalfLife
|
30–81 minutes
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C19H21NO4
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
naloxone
|
|
gptkbp:IUPACName
|
gptkb:(5α)-4,5-Epoxy-3,14-dihydroxymorphinan-6-one
|
|
gptkbp:KEGGID
|
D08367
|
|
gptkbp:legalStatus
|
prescription only (US)
over-the-counter (US, some states)
|
|
gptkbp:mechanismOfAction
|
delta-opioid receptor antagonist
kappa-opioid receptor antagonist
mu-opioid receptor antagonist
|
|
gptkbp:meltingPoint
|
200–205 °C
|
|
gptkbp:MeSH_ID
|
D009294
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:notEffectiveAgainst
|
non-opioid overdose
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:proteinBinding
|
45%
|
|
gptkbp:PubChem_CID
|
5284596
CHEMBL1044
DB01183
|
|
gptkbp:routeOfAdministration
|
intramuscular
subcutaneous
intravenous
intranasal
|
|
gptkbp:sideEffect
|
nausea
vomiting
hypertension
sweating
tachycardia
agitation
|
|
gptkbp:solubility
|
soluble in water
|
|
gptkbp:UNII
|
PBK1S1M032
|
|
gptkbp:usedFor
|
opioid overdose
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Thebaine
gptkb:Heroin
gptkb:Buprenorphine
gptkb:Morphine
gptkb:Naltrexone
gptkb:Emergency_Medicine
gptkb:Narcan
gptkb:Anesthesia
gptkb:opioid
gptkb:Overdose
gptkb:buprenorphine
|
|
gptkbp:bfsLayer
|
6
|